AZD4512 / AstraZeneca - LARVOL DELTA

AZD4512: Data from P1/2 ALLight trial (NCT07109219) for ALL post 2027 (AstraZeneca) - Q1 2026 Results: Data from P1/2 Lumi-NHL trial (NCT07123454) for r/r/ B-cell NHL post 2027

P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=83 | Recruiting | Sponsor: AstraZeneca

Monotherapy • Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

D9890C00001: A trial to learn how safe AZD4512 is with and without other cancer drugs and how it works in the bodies of people with B-cell non-Hodgkin lymphoma (B-NHL) (clinicaltrialsregister.eu) - P1/2 | N=12 | Recruiting | Sponsor: AstraZeneca AB

Monotherapy • New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ALLight D9891C00001: A trial to learn how safe AZD4512 is and how it works in the bodies of people with B-cell acute lymphoblastic leukemia (B-ALL) (clinicaltrialsregister.eu) - P1/2 | N=13 | Recruiting | Sponsor: AstraZeneca AB

Monotherapy • New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=83 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies (ASH 2025) - "Toxicology studies showed thatAZD4512 was well-tolerated, with no unexpected side effects. Collectively, these findings highlightAZD4512 as a promising therapeutic candidate for the treatment of patients with B-ALL and B-NHL."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • KMT2A

Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=91 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=91 | Not yet recruiting | Sponsor: AstraZeneca

Monotherapy • New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology